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Summary
Alzheimer’s disease (AD) is a devastating neurodegenerative
disorder that results in loss of memory and cognitive function,
eventually leading to dementia. A key neuropathological event
in AD is the cerebral accumulation of senile plaques formed by
aggregates of amyloid-b-peptides (Ab). Ab results from two se-
quential endoproteolytic cleavages operated on the amyloid-b
precursor protein (AbPP), an integral membrane protein with a
single-membrane spanning domain, a large extracellular N-ter-
minus and a shorter, cytoplasmic C-terminus. First, b-secretase
(BACE1) cleaves AbPP at the N-terminal end of the Ab
sequence to produce a secreted form of AbPP, named sAbPP,
and a C-terminal membrane-bound 99-aminoacid fragment
(C99). Then, c-secretase cleaves C99 within the transmembrane
domain to release the Ab peptides of different lengths, predomi-
nantly Ab1-40 and Ab1-42.  2012 IUBMB
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The expression and the enzymatic activity of b-secretase
(BACE1) are increased in the brains of Alzheimer’s disease (AD)
patients. Moreover, age-related stress may increase BACE1 levels
and drive AD pathogenesis. The precise mechanisms of this upregula-
tion are not completely understood; here, we discuss the relevance of
a number of recently identified transcription factors as well as post-
transcriptional modifications and activation of intracellular signaling
molecules for the regulation of BACE1 expression in the brain.
BACE1 STRUCTURE
The BACE1 gene encodes for a protein of 501 amino acids
(1–5) consisting of an N-terminal signal peptide (residues, 1–21),
followed by a prodomain (residues, 22–45), a protease domain
(residues, 46–460) which contains two consensus motif character-
istic of an aspartyl protease active site (DTGS, at residues 93–96,
and DSGT, at residues 289–292), a single transmembrane domain
(residues, 461–477), and a short cytosolic domain (residues, 478–
501).
The crystal structure of BACE1 is complex and the enzyme’s
active site is larger and less hydrophobic than that of other human
aspartic proteases (6), making it a difficult target for designing
inhibitors (7). A distinctive feature of BACE1 is its anchoring in
the membrane through a single-transmembrane domain, which
allows the placement of its catalytic domain in the same orientation
as APP (8). At an optimal pH of 4.0–5.5, BACE1 is expected to
operate in acidic intracellular compartments such as the trans-Golgi
network, endosomes, and lysosomes (2, 3, 5).
BACE1 full maturation involves various post-translational
modifications. Analysis of its primary sequence revealed four
sites of N-glycosylation within the protease domain (Asn residues
153, 172, 223, and 354), as confirmed by site-directed mutagene-
sis experiments (9, 10). BACE1 undergoes cotranslational N-gly-
cosylation in the ER, as demonstrated by treatment with tunica-
mycin, which inhibits the first step of glycoprotein synthesis.
Further complex glycosylation is achieved as BACE1 transits
through the Golgi (11). There is evidence that sulfation can also
occur on the N-glycosylation sites as part of BACE1 maturation
(12). Depending on experimental conditions and individual cell
lines’ glycosylation machinery, the molecular weight of BACE1
has been reported to be between 70 and 75 kDa for the mature
protein (8, 9, 11, 13), and between 60 and 70 kDa for its imma-
ture forms (8, 9, 11, 13). The carbohydrate content of BACE1
accounts for about 30% of its molecular weight, similar to other
endosomal/lysosomal resident proteins.
BACE1 and the Pathogenesis of Sporadic
and Familial AD
The majority of AD cases are sporadic with late onset and
no defined cause. Several reports show increased levels and
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activity of BACE1 protein in the brain of sporadic AD patients,
compared to normal age controls (14–16). Oxidative stress (OS)
is potentially involved in the pathogenesis of sporadic AD as it
is correlated with age as much as AD (17). More causally, OS
and Ab are interconnected to each other as Ab induces OS (18)
and OS in turn increases the production of Ab (19).
We have proposed a sequence of events that link OS,
BACE1 induction, and apoptotic cell death mediated by an
overproduction of Ab1-42. First, we have shown that oxidant
agents and 4-hydroxynonenal significantly increase the expres-
sion, protein levels, and activity of BACE1 in NT2 neurons (20,
21). These events are followed by both an overproduction of
Ab peptides and morphological signs of apoptotic cell death
(22). Then, we have found that OS increases the c-secretase ac-
tivity both in vitro and in vivo, and that the increased BACE1
expression induced by OS is regulated by the c-secretase activ-
ity (23). These results have important implications for the
pathogenesis of sporadic AD. First, they suggest that OS, sec-
ondary to different AD risk factors, can increase the expression
of both secretases, thereby enhancing Ab production. Second,
our data revealed the existence of a positive feedback loop in
which the c-secretase activity regulates BACE1 expression, a
finding confirmed by Jo et al. (24).
A strong inflammatory reaction is present in AD brain, and
long-term nonsteroidal anti-inflammatory drugs (NSAID) use
reduces the risk of AD, suggesting that inflammation may play
an important role in AD pathophysiology (25).
In fact, the BACE1 promoter also bears a binding site for
the transcriptional regulator proliferator-activated receptor c
(PPARc) (26). Activation of PPARca by NSAIDs or PPARc
agonists causes repression of BACE1 gene promoter activity,
whereas proinflammatory cytokines that reduce PPARcc levels
lead to increased BACE1 mRNA (26).
The activity of BACE1 is increased also in the familial early
onset AD (FAD). We showed that PS1 mutations increase
BACE1expression and that this effect is dependent on the pres-
ence of APP and is proportional to the amount of Ab1-42 pro-
duced and secreted in the extracellular milieu (27). This novel
effect of PS1 mutations implies the existence of a positive feed-
back loop from the c- to the BACE1 cleavages of APP in which
Ab1-42 is the APP derivative that influences/modulates BACE1
transcription through the activation of the c-Jun NH2-terminal
kinase (JNK)/AP1 cascade (28). PS1 mutations result in a wide
and heterogeneous clinical phenotype that includes atypical pre-
sentations, such as ataxia, paraparesis, and epilepsy (29–31).
The upregulation of BACE1 determined by PS1 mutations may
contribute to determine FAD phenotype. Indeed, the overexpres-
sion of BACE1 increases the production of N-terminal-truncated
Ab species (32). We and others (33) have shown that the com-
position of soluble Ab reflects the pathological and clinical phe-
notype of Ab amyloidosis and that the prevalence of N-termi-
nal-truncated Ab1-42 peptides correlates with the rate of aggre-
gation and with the degree of toxicity of the mixture of Ab
species (34). Moreover, recent data obtained with different ani-
mal models of Ab amyloidosis support the hypothesis that the
composition of Ab species, indicated as ‘‘Ab strains’’ (35–37),
dictates the conformation of Ab-soluble aggregates, which in
turn produces different pathological phenotypes. The mecha-
nisms of BACE1 upregulation vary from transcriptional, post-
transcriptional, translational, post-translational, and degradation
control.
Transcriptional Control of BACE1
The human BACE1 gene spans approximately 30 kb on
chromosome 11q23.2 and includes nine exons. BACE1 gene
promoter has a complex structure, divided into two distinct pro-
moter regions, carrying several transcription actor-binding sites,
many of which are organized in repeats, typical of an inducible
protein (38).
Different signaling pathways and transcription factors, such
as sp1, NF-jB, JNK/AP-1, hypoxia inducible factor 1 (HIF-1)a,
and p25/cdk55/STAT3 have been suggested to control BACE1
transcription.
Sp1. One of the first studies that provides information about
the molecular mechanism regulating BACE1 gene expression
came from Christensen and collaborators (2004) and showed
that the transcription factor sp1 plays a significant role in this
regulation: sp1 overexpression facilitates BACE1 promoter ac-
tivity, whereas lack of endogenous sp1 protein in sp1-KO cells
markedly reduces the transcriptional activation of BACE1 gene
(39). The relevance of this study was recently confirmed by a
completely different experimental approach. Prenatal lead expo-
sure in rats induces a robust and long-lasting increase in Sp1
expression which results in increased APP mRNA and protein
BACE1 expression and Ab generation (40). Thus, sp1 is
involved in amyloidogenesis by a concurrent activation of APP
and BACE1 expression.
The crucial role of sp1 in regulation of BACE1 was recently
supported by the finding that molecules able to decrease Ab
production interfere with sp1 transcriptional pathway (41).
These findings demonstrate that interference with sp1 transcrip-
tional pathways can lower pathogenic intermediates associated
with AD.
On the other hand, 12/15-lipoxygenase, an enzyme widely
distributed in the central nervous system, increases the amyloi-
dogenic processing of APP through a sp1-mediated transcrip-
tional control of BACE1 levels (42).
NF-jB. Another transcription factor that plays a role in AD
pathogenesis by regulating BACE1 levels is NF-jB. The sup-
pressor role of NF-jB is supported indirectly by the evidence
that the lipid peroxidation product 4-hydroxynonenal inhibits
both constitutive and inducible NF-jB activities (43) and
increases BACE1 expression (20, 22).
Moreover, in addition to suppress BACE1 expression, the
NF-jB signaling pathway is one of the major neuroprotective
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pathways in AD (44). Treatment of neuronal cells with low,
nontoxic Ab peptide concentrations induces NF-jB activation
(45) and leads to neuroprotection against subsequent treatment
with toxically high Ab peptide concentrations (46). Vice versa,
the IjB kinase inhibitor, BMS345541, that completely blocks
NF-jB transcriptional activity, fully reverses the Ab1-42-
induced increase of BACE1 promoter transactivation (47).
We recently demonstrated a novel pathogenetic mechanism
involving the advanced glycated end-products (AGEs), which
contributes to Ab accumulation (48). In streptozotocin diabetic
rats, as well as in SK-N-BE-differentiated neuroblastoma cells,
two different AGEs, pentosidine and glyceraldehyde-derived
pyridinium, were able to upregulate BACE1 expression through
their binding with the receptor of advanced glucation products
(RAGE). The binding was followed by a strong production of
reactive oxygen species (ROS) and by an activation of the NF-
jB pathway, which is known to be activated by RAGE (49). In
this context, it has been recently reported that minocycline, a
potential neuroprotective tetracycline derivative (50), downregu-
lates BACE1 expression and thus Ab accumulation in the hip-
pocampus of diabetic mice inhibiting NF-jB pathway activation
(51).
Moreover, other different compounds lower BACE1 activity
through the inhibition of NF-jB pathway, as described recently
(52, 53), suggesting that this pathway could be a useful thera-
peutic target.
Altogether, these data indicate that NF-jB regulation of
BACE1 transcription may be altered in AD owing to chronic
stress. The failure in the transcriptional regulation by NF-jB of
BACE1 may in part account for increased BACE1 transcription
and subsequent amyloidogenic APP processing in a cell type-
specific manner. The functional NF-jB site in the BACE1 pro-
moter is stimulatory in activated astrocytes and Ab-exposed
neuronal cells and repressive in neuronal and quiescent astro-
cytic cells.
Finally, it has been recently found that NF-jB differentially
regulates Ab production at physiological and supraphysiological
Ab concentrations by modulating transactivation of bAPP and
secretase promoters. Thus, under physiological conditions, NF-
jB regulates Ab homeostasis, whereas it contributes in increas-
ing Ab production in the pathological context (54).
It is thus possible that BACE1, given its complex promoter
structure and its relationships with heterogeneous signaling
pathways (38, 47, 55), can be part of a pool of enzymes that
respond to cellular stress or homeostasis modifications. As in
the case of glucose lowering signals, where insulin and metfor-
min have opposite effects on amyloidogenesis and BACE1 reg-
ulation (56), in some pathways the same endpoint can result in
opposite outcomes on BACE1 activation. This may be owing to
the fact that BACE1 is working together with still undefined
partners to fulfill a cellular response.
HIF-1a. Although AD is classified as a neurodegenerative de-
mentia, there is epidemiologic and pathologic evidence of an
association with vascular risk factors and vascular disease (57)
with which AD could share pathogenetic mechanisms. Cerebral
hypoperfusion and hypoxia trigger hypometabolic, cognitive,
and degenerative changes in the brain and contributes to the
pathologic process of AD (58).
Indeed, hypoxia increases the expression and activity of
BACE1, as shown in vitro as well as in AD transgenic model
(59, 60). One proposed mechanism of the effect of hypoxia on
BACE1 upregulation is that the activation of hypoxia inducible
factor 1 (HIF-1), a transcription factor that regulates oxygen ho-
meostasis, binds to BACE1 promoter, and regulates its gene
expression (60). We more recently extended these findings,
showing both in vivo and in vitro that hypoxia upregulate
BACE1 mRNA expression in a biphasic manner, through two
distinct mechanisms: 1) an early release of ROS from mitochon-
dria and 2) a late activation of HIF-1a (61).
The early posthypoxic upregulation of BACE1 recapitulates
the cascade of events induced by oxidant agents: an increase of
BACE1 expression and activity, whereas chronic hypoxia trig-
gers the second mechanism of BACE1 upregulation, HIF-1a
activation.
HIF-1a seems to be the pathway link between cerebrovascu-
lar dysfunctions and AD. It has been recently observed that, in
rat brain capillary endothelial cells, oxygen glucose deprivation
treatment elicits a strong production of Ab1-42 peptide through
a mechanism that involves the HIF-1-mediated BACE1 upregu-
lation (62). The inhibition of the HIF-1a pathway could provide
a new insight into prevention and treatment of AD. It is worth
noting that salidroside, a compound extracted from the root of
Rhodiola rosea, which has been used in traditional Tibetan
medicine since long ago, is able to attenuate abnormal process-
ing of amyloid precursor protein induced by hypoxia in SH-
SY5Y cells, decreasing BACE1 expression and protein levels of
HIF-1a (63).
AP1/JNK. The upregulation of BACE1, induced by OS,
requires the activation of JNK-AP1 pathway (22). This pathway
is activated in AD brain (64–66), to respond to cell stress and
to mediate apoptosis (67–70). Moreover, JNK activation is asso-
ciated with age-dependent amyloid plaque deposition, tau phos-
phorylation, and the loss of synaptophysin in a Tg2576/PS1
double transgenic mice (71–73). We and others have also dis-
covered that BACE1 activation is regulated by the c-secretase
activity, and requires the activation of JNK-AP1 pathway (23,
25). Then, we have found that Ab1-42 is the product of the c-
secretase cleavage that upregulates BACE1 expression (23, 27)
and that Ab1-42 increases BACE1 gene transcription through
the activation of JNK/c-jun signaling pathway (28). Although
the mechanisms of JNK activation by Ab1-42 remain unclear, it
is likely that JNK is activated by Ab1-42 indirectly, perhaps by
the interaction of Ab1-42 with yet unidentified receptors.
Indeed, different proteins, such as APP itself, NMDA, TrkA,
and LRP family of receptors, interact with Ab peptides (74,
75). This could lead not only to BACE1 regulation but also to
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the control of a pool of genes involved in a specific cellular
function. The knowledge of the genes activated by Ab may be
determinant to understanding the precise series of events, lead-
ing to neuronal dysfunction and degeneration in AD.
Post-transcriptional Control of BACE1
Additional nontranscriptional mechanisms have been
hypothesized to account for increased BACE1 protein levels
and activity.
BACE-1 translation is regulated at multiple stages, consistent
with the presence of a long and highly conserved transcript
leader (76, 77). In particular, the 50-UTR represses the rate of
BACE1 translation (78), and alternative splicing of the tran-
script leader can influence the rate of translation in a tissue-de-
pendent manner (76). A detailed mutagenesis analysis suggested
that the GC-rich region of the 50-UTR acts as a ‘‘translation bar-
rier’’ (78). The presence of several upstream ATGs also
strongly reduces the translation of the main open reading frame,
which implies that BACE1 translation might increase in condi-
tions that favor phosphorylation of the translation eukaryotic
initiation factor-2a (eIF2a) (76). More recent studies have
shown that cellular energy deprivation (glucose deprivation in
cell culture) produces a post-transcriptional increase in BACE1
levels, which is indeed mediated through increased eIF2a phos-
phorylation (78). These observations in vitro correlated with in
vivo studies in AD transgenic (Tg2576) mice, in which chronic
energy inhibition with 2-deoxyglucose or 3-nitropropionic acid
was shown to increase eIF2a phosphorylation, BACE1 levels,
and amyloidogenesis (79). A BACE1 protein stability can also
be influenced by the lysosomal pathway (80). Tesco and col-
leagues (81) have demonstrated that lysosomal but not proteoso-
mal inhibitors lead to the accumulation of both endogenous and
ectopically expressed BACE1 in a variety of cell types includ-
ing primary cortical neurons. Moreover, it has been shown that
BACE1 accumulates in late endosomes/lysosomes after inhibi-
tion of lysosomal hydrolases, indicating that BACE1 is trans-
ported in late endosomes/lysosomes where it can be degraded
via the lysosomal pathway.
Intriguingly, GGA (Golgi-localized c-ear-containing ARF-
binding proteins) 1, 2, and 3, involved in the transport from the
Golgi complex to the endosomes of proteins containing the
DXXLL signal have been shown to bind the BACE1 acidic
dileucine motif (82). Moreover, phosphorylation of serine 498
in BACE1 increases their binding (83). Also, the downregula-
tion of GGAs significantly increases the levels of BACE1 in
endosomes and GGAs may be necessary for BACE1 transport
back to trans Golgi (84).
More recently, it has been shown that GGA3, unexpectedly,
regulates levels and activity of BACE1 by interaction with
ubiquitin and not via di-leucine motif (85), thus a GGA3 mutant
with reduced ability to bind ubiquitin is unable to regulate
BACE1 levels and activity. These findings are in agreement
with increasing evidence, showing that GGAs bind ubiquitin
and traffic both synthetic and endosomal ubiquitinated proteins
to lysosomes (86, 87). As levels of BACE1 are elevated in AD
brains and they are inversely correlated with GGA3 levels (85),
these studies suggest that therapies able to increase GGA3
expression in the brain may represent a potential treatment for
AD.
In addition to GGAs, reticulons, a novel gene family that
were shown to participate in all apoptosis signaling pathways,
may be novel players in AD pathogenesis (88).
Thus, the reticulon/Nogo has been shown to interact with
BACE1 and regulate its activity (89). Moreover, the overexpres-
sion of reticulon 3 (RTN3) also results in the retention of
BACE1 in the endoplasmic reticulum and the reduction of Ab
production both in vivo and in vitro (90).
Additional post-transcriptional mechanisms have been sug-
gested to lead to increased BACE1 protein levels and activity.
It has been found that the expression of BACE1 antisense tran-
scripts, which respond to cellular stresses and to Ab itself, sta-
bilizes BACE1 mRNA (91); moreover, alternative splicing of
BACE1 pre-mRNA acts as a control system as well (92).
Ab1-42 Modulates BACE1 Levels Through Both
Transcriptional and Post-transcriptional Mechanisms
It has been suggested that Ab might play a role not just as a
toxic peptide, but also as a functional signaling molecule. The
most convincing evidence was obtained from the study of
Kamenetz et al. (93), showing that Ab is the player of a nega-
tive feedback loop that controls the synaptic activity. These
data agree with the finding that Ab production is proportional
to the level of brain activity, as demonstrated in the recovery
from severe cranial trauma (94).
Gatta et al. (95) performed a microarray assay, showing that
exposure of neuroblastoma cells to an Ab1-42-aluminum com-
plex is followed by a selective change in gene expression; the
activated genes are involved in the modulation of calcium ho-
meostasis, glutamatergic transmission, OS, inflammation, and
apoptosis (95).
We showed an induction of BACE1 occurring at low con-
centrations of monomeric preparations of Ab1-42 and starting
within minutes of treatment (96). Although this may seem a
short time interval, specific gene transcription can occur within
minutes for certain cellular processes (97). It is likely that
BACE1 is part of a cellular response aimed at fast adaptation to
extracellular stimuli.
We have also found that Ab1-42 downregulates the activity
of ubiquitin C-terminal hydrolase L1 (Uch-L1), through the
activation of NF-jB pathway, and that this event is associated
to an upregulation of BACE1 (Fig. 1) (98).
Uch-L1 is an abundant neuronal enzyme, representing 1–2%
of total soluble brain proteins (99). Uch-L1 has two enzymatic
activities. The first one, known as hydrolase, removes and
recycles ubiquitin molecules from the degraded proteins. This
recycling action is crucial for the degradation process as it gen-
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erates free monomeric ubiquitin which can be reused for further
reactions of ubiquitination (100). The second one, called ubiqui-
tin ligase, links ubiquitin molecules, thus generating polyubiqui-
tine chains that tag proteins for disposal. To play this activity,
the enzyme has to be dimerized in vitro and remains unclear
whether this activity also occurs in vivo (100). Several lines of
evidence suggest a possible link between Uch-L1 activity and
AD: the activity of Uch-L1 is downregulated in AD brain (101,
102) and its levels are inversely proportional to the number of
neurofibrillary tangles in the brains of sporadic AD patients
(102).
Moreover, Ab increases in spontaneous neurological mutant
with axonal dystrophy in the gracile tract of the medulla oblon-
gata and spinal cord of mice lacking Uch-L1 expression (103).
In a mouse model of AD, the double transgenic mouse overex-
pressing APP together with mutant presenilin 1 (APP/PS1
mice), the Uch-L1 protein expression, and activity in brain are
also decreased (104). Downregulation of Uch-L1 seems to be at
least in part responsible for the impairment of long-term poten-
tiation (LTP) (105). The effect of Ab on LTP is mediated by
the inhibition of phosphorylation of the cAMP response ele-
ment-binding protein (CREB), a transcription factor activated
by cAMP-dependent protein kinase A (PKA) (106). The inhibi-
tion of Uch-L1 activity would lead to impairment of the degra-
dation of the PKA regulatory subunit, a decrease in its activity,
and subsequently downregulation of CREB-dependent transcrip-
tion (104).
The correlation between the inhibition of Uch-L1 and the up-
regulation of BACE1 was previously reported by Zhang et al.
(107), who showed that inhibition of Uch-L1 significantly
increases BACE1 protein levels in a time-dependent manner.
Moreover, overexpression of Uch-L1 decreased APP c-terminal
fragment C99 and Ab in the Uch-L1-null AD mice (107).
We extended these findings, showing that the decrease of
Uch-L1 activity is related with the Ab1-42-mediated activation
of NF-jB pathway (98). Recently, the Uch-L1 gene promoter
region was cloned and functionally identified, and a NF-jB-
binding element within its promoter region identified. NF-jB
signaling downregulates Uch-L1 expression and mediates the
inhibitory effect of lipopolysaccharide and tumor necrosis fac-
tor-a (TNF-a) on Uch-L1 expression (108).
We next demonstrated that these effects were not only con-
comitant but also that the decrease in Uch-L1 rebounded on
BACE1 degradation (98).
Thus, our data indicate that BACE1 is transported in the late
endosomal/lysosomal compartment where it is degraded via the
lysosomal pathway (81), and not in the proteosome.
The involvement of lysosomal pathway in BACE1 degrada-
tion was confirmed by three findings. 1) Treatment of cells with
lysosomal inhibitors was followed by a significant accumulation
of BACE1. 2) Confocal laser scanner microscopy demonstrated
that BACE1 colocalizes with the lysosome marker LAMP-1. 3)
We have determined that BACE1 is Lys-63-linked ubiquiti-
nated. Kang et al. (85) previously reported a lys-63-linked ubiq-
uitination of BACE1, showing that GGA3 regulates the BACE1
degradation via the interaction with ubiquitin. In this scenario,
loss of functional Uch-L1 could lead to inadequate ubiquitina-
tion of BACE1 mediated by a decrease in free ubiquitin.
Finally, we found that the Uch-L1 inhibitor LDN-57444 as
well as Ab1-42 impairs the activity of cathepsin D, considered
a marker of lysosomal activity (98).
Lysosomal dysfunction has been linked to a spectrum of de-
generative diseases (109), many of which involve the CNS
(110). Alterations of the endosome/lysosome system have also
been previously described in AD (111). It has been shown that
BACE1 and Ab are enriched in lysosome-related autophagic
vesicles in APP transgenic mouse models (112). The autophagic
vesicles accumulate also in dystrophic neuritis in AD brains
(113).
Thus, our findings described a transcriptional role of Ab1-42
that mediates the inhibition of Uch-L1 and the upregulation of
BACE1 mediated by NF-jB pathway activation and a post-tran-
scriptional mechanism that impairs BACE1 lysosomal degrada-
tion (98).
CONCLUSIONS
To summarize, protein BACE1, the levels of which are ele-
vated in the brain of sporadic AD patients, is controlled both
transcriptionally and post-transcriptionally by molecules which
have been recently identified. Different signaling pathways and
transcription factors, such as sp1, NF-jB, JNK/AP-1, and p25/
cdk55/, HIF-1a 50-UTR, and p25/cdk55/STAT3 STAT3 influ-
ence the rate of BACE1 translation, whereas several upstream
Figure 1. Pathogenetic hypothesis in which Ab1-42 mediates a
BACE1 increase and a parallel Uch-L1 decrease through the
activation of NF-jB pathway. The Uch-L1 decrease then further
fosters BACE1 activity interfering with its lysosomal degrada-
tion through a post-transcriptional mechanism.
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ATGs, eIF2a phosphorylation, GGA3, reticulon/Nogo, and Uch-
L1 play a role in post-transcriptional control. All these regula-
tory molecules represent potential targets for the development
of compounds that can interfere with BACE1 expression/activ-
ity, to be introduced in the clinic as drugs in the therapy of AD.
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